Overview

Public BiotechLSD

Clinical-stage biotech developing next-generation serotonin agonists for epilepsy and neuropsychiatric disorders. Lead program BMB-101 showed 73% seizure reduction in Phase 2 trials for drug-resistant epilepsies.

Visit Website

New York, NY

$740M
Market Cap
2017
Founded
0
Open Roles

Open Positions

No open positions at this time

Clinical Pipeline(1)

Unknown·N/A·LSD

Investigating Lysosomal Storage Diseases in Minority Groups

Lysosomal Storage Disorders
NCT02120235